Story
Telix Pharmaceuticals Gains FDA Approval for Brain Cancer Imaging Agent
Telix Pharmaceuticals Ltd (ASX:TLX) has received U.S. Food and Drug Administration (FDA) approval for its brain cancer imaging agent, Pixclara, a development that triggered a significant rally in the company's shares. The U.S.-Australian company announced the regulatory milestone on Monday.
Details of the Approval
The FDA approved Telix's New Drug Application, which will allow for broad access to Pixclara across the United States. In a statement, Telix described the product as a radioactive diagnostic drug used for imaging glioma, a type of brain cancer.
The company noted that Pixclara is the first drug of its kind to receive FDA approval. This regulatory clearance is expected to create a significant new revenue stream for the company by opening up the U.S. market.
Market Reaction
AdInvestors reacted positively to the announcement in Sydney trading. Key figures on the market move include:
- Shares in Telix jumped as much as 12% to a high of A$17.65.
- The initial gains later tapered, with the stock finishing the session up 2.6%.
The approval adds to a strong performance for the company's stock, which is up nearly 43% so far in 2026, according to data from Investing.com.
Read next
More on Stocks
FTC Orders Walmart, Uber, Delta to Disclose Data on Personalized Pricing
The U.S. Federal Trade Commission is demanding nine major companies, including leading retail, travel, and gig economy firms, to provide information on how they use consumer data for setting individual prices and wages.
Google Launches Gemini 4 Carbon AI Model to Bolster Cybersecurity Capabilities
Alphabet's Google has unveiled Gemini 4 Carbon, its latest AI model specifically designed for advanced cybersecurity tasks like vulnerability detection and secure code generation. The launch escalates competition with rivals OpenAI and Anthropic in the enterprise AI market.
Oracle Shares Surge After Unveiling $225 Billion Revenue Target for 2030
Oracle stock rose sharply after the company presented a long-term financial outlook targeting at least $225 billion in annual revenue by fiscal 2030, driven by its expanding AI infrastructure business.
DOJ Scrutinizes Nvidia's $12.9B Hugging Face Deal Amid Broader Antitrust Probe, Sources Say
The U.S. Department of Justice is reportedly examining Nvidia's planned $12.93 billion acquisition of AI platform Hugging Face as part of a wider, ongoing antitrust investigation into the chipmaker's market conduct.